Drug Profile

Research programme - IL-17 antagonist - DICE Therapeutics

Alternative Names: IL-17 antagonist-DICE-Therapeutics; Novel scaffold program #1 (Fast follower); Novel scaffold program #2

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DiCE Molecules
Developer DICE Therapeutics
Class Antipsoriatics; Small molecules
Mechanism of Action Interleukin 17 receptor antagonists; Protein-protein interaction inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2025 No recent reports of development identified for preclinical development in Psoriasis in USA (PO)
09 Aug 2023 DICE Therapeutics has been acquired by Eli Lilly and Company
19 Oct 2021 Preclinical trials in Immunological disorders in USA (PO) befor October 2021 (DICE Therapeutics pipeline, October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com